Compare ERH & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERH | CSBR |
|---|---|---|
| Founded | 2004 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.7M | 82.7M |
| IPO Year | N/A | 2015 |
| Metric | ERH | CSBR |
|---|---|---|
| Price | $12.41 | $6.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 25.1K | 5.7K |
| Earning Date | 01-01-0001 | 06-22-2026 |
| Dividend Yield | ★ 8.85% | N/A |
| EPS Growth | N/A | ★ 161.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,900,000.00 |
| Revenue This Year | N/A | $4.84 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.98 | $5.50 |
| 52 Week High | $13.07 | $10.25 |
| Indicator | ERH | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 52.23 | 50.42 |
| Support Level | $11.57 | $6.11 |
| Resistance Level | $12.55 | $6.24 |
| Average True Range (ATR) | 0.17 | 0.21 |
| MACD | -0.06 | 0.06 |
| Stochastic Oscillator | 34.63 | 78.75 |
Allspring Utilities and High Income Fund is a diversified closed-end management investment company. Its investment objective is to seek a high level of current income and moderate capital growth, with an emphasis on providing tax-advantaged dividend income. The company allocates a majority of its total assets to a sleeve that places a focus on common, preferred, and convertible preferred stocks of utility companies and the rest of its total assets to a sleeve of U.S. dollar denominated below investment grade (high yield) debt.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.